Compare Tripadvisor Inc Common Stock (TRIP) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tripadvisor Inc Common Stock vs State Street SPDR S&P Biotech ETF — how do they compare? Tripadvisor Inc Common Stock trades at $13.82 (market cap $1.68B), while State Street SPDR S&P Biotech ETF trades at $154.41. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Tripadvisor Inc Common Stock nearer its low. Which is the better fit depends on your goals.
| TRIP | XBI | |
|---|---|---|
Market Cap | $1.68B | — |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $19.14 | $164.28 |
52-Week Low | $9.24 | $85.16 |
Enterprise Value | $1.80B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tripadvisor (TRIP) trades at $13.8, down 5.35% over 24 hours. The stock shows a bullish technical signal with moving averages supporting an uptrend, while oscillators are neutral. Fundamentally, revenue grew to $1.89B in 2025 with a net income margin of 0.99%, but recent earnings misses and a high P/E of 131.09 raise valuation concerns. The recent $700M sale of TheFork to American Express simplifies the business and provides a cash infusion.
Outlook is mixed: the sale of TheFork and focus on core experiences offer strategic clarity, but stiff competition and macroeconomic pressures pose risks. Analyst consensus is a 'Hold' with a $13.87 price target, slightly above the current price, indicating limited near-term upside amid cautious sentiment.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
